Johnson & Johnson
JNJ
Company Profile
Business description
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Contact
One Johnson and Johnson Plaza
New BrunswickNJ08933
USAT: +1 732 524-0400
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
134,400
Johnson & Johnson News & Analysis
markets
4 charts on the US rotation out of growth and tech stocks
Value stocks among financials, healthcare and consumer defensive sectors are supporting the market.
stocks
3 undervalued US value shares with moats
Value continues to underperform but it may be a function of how we think about the investing style.
stocks
Warren Buffet's latest buys and sells
Undervalued stocks in Berkshire Hathaway’s portfolio, as well as its latest buys and sells from its third-quarter 2023 13F filing.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,633.10 | 66.10 | 0.77% |
| CAC 40 | 7,255.01 | 41.69 | 0.58% |
| DAX 40 | 19,322.59 | 176.42 | 0.92% |
| Dow JONES (US) | 44,296.51 | 426.16 | 0.97% |
| FTSE 100 | 8,262.08 | 112.81 | 1.38% |
| HKSE | 19,229.97 | 371.14 | -1.89% |
| NASDAQ | 19,003.65 | 31.23 | 0.16% |
| Nikkei 225 | 38,283.85 | 257.68 | 0.68% |
| NZX 50 Index | 13,041.90 | 276.66 | 2.17% |
| S&P 500 | 5,969.34 | 20.63 | 0.35% |
| S&P/ASX 200 | 8,393.80 | 70.80 | 0.85% |
| SSE Composite Index | 3,267.19 | 103.21 | -3.06% |